Controversies in the adjuvant therapy of high-grade gliomas.
about
Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targetsActionable molecular biomarkers in primary brain tumors.Assessment and treatment relevance in elderly glioblastoma patients.The clinico-oncologic outcomes of elderly patients with glioblastoma after surgical resection followed by concomitant chemo-radiotherapyIncreased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption.Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro.Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.High levels of cellular proliferation predict pseudoprogression in glioblastoma patientsDistribution of polymer nanoparticles by convection-enhanced delivery to brain tumors.Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomasVaccines for glioblastoma and high-grade glioma.Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.PARK2 negatively regulates the metastasis and epithelial-mesenchymal transition of glioblastoma cells via ZEB1.Pushing the limits of glioma resection using electrophysiologic brain mappingCracking the glioma-NK inhibitory code: toward successful innate immunotherapy.Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas.Should the subventricular zone be part of the "rad" zone?Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
P2860
Q28541360-87E049E8-0C58-428C-B341-4BB833BF8F5AQ33772355-9F8240CD-A432-40FA-9D61-5CACA55ECE3CQ34359650-E443F3A7-6657-470C-B9A2-1259EB954A99Q34509456-F2F99F02-6161-47AB-A6AD-2419F8F11279Q34987685-981777E7-9B0B-4DE0-90F7-CC47567C8226Q35920319-A9BB845F-245E-4F89-A809-52332D8C14E0Q36197395-6E02014F-B180-403E-94EE-72BA17A15010Q36236484-9572E58C-F511-41A3-B6B5-434A65FD9BCAQ36645695-126A0F30-4352-4F5D-B0DE-B49D4E403354Q36971160-04DFB35C-4069-4BF1-98AC-AB4B606834B2Q37023701-B2261776-8A78-4877-AA0B-E56CA5502553Q37892597-3B396635-9490-4F69-9AB2-AE57C8F39524Q39309511-B116ECD9-2CEF-4397-837E-A8E4A06AD0B0Q41575088-0D53672A-E7F6-42C1-8F15-5B548F96D3E9Q41611419-6592CEB8-F3EE-4A75-8FEB-658B02F8F5CAQ42367453-411E51CF-CA25-4F00-B41D-682DA133BEC6Q43103834-7ADBC789-9BE4-4A47-8CD4-972C5DA14D10Q45183143-1BD92CDB-0021-4A4C-8988-D32255AB6E74Q48775175-57E099C7-DD20-4FFF-B65E-A4154DC05BEBQ53108051-9C7B8479-F1F7-410A-AB39-70E20C1AB13A
P2860
Controversies in the adjuvant therapy of high-grade gliomas.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Controversies in the adjuvant therapy of high-grade gliomas.
@ast
Controversies in the adjuvant therapy of high-grade gliomas.
@en
type
label
Controversies in the adjuvant therapy of high-grade gliomas.
@ast
Controversies in the adjuvant therapy of high-grade gliomas.
@en
prefLabel
Controversies in the adjuvant therapy of high-grade gliomas.
@ast
Controversies in the adjuvant therapy of high-grade gliomas.
@en
P2860
P1433
P1476
Controversies in the adjuvant therapy of high-grade gliomas.
@en
P2093
Matthias Holdhoff
Stuart A Grossman
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0335
P577
2011-02-21T00:00:00Z